Physician

Eugene J Bauerlein, MD

According to 2025 Medicare claims, Eugene Bauerlein, MD (NPI: 1841234291) practices advanced heart failure and transplant cardiology in the Miami-Miami Beach-Kendall, FL market, with the plurality of this provider's patient population coming from Miami-Dade, FL. This provider's primary affiliated billing organization is UNIVERSITY OF MIAMI (NPI: 1831799055; TIN: 592579938) and primary practice location at 33136-1005.

Bauerlein's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 68 traditional Medicare patients, billed 451 HCPCS/CPT codes, and received $30,017 in Medicare payments. The top billing code was 99215 (Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more). Part D data shows 511 prescription claims across 82 beneficiaries totaling $112,386 in drug costs, led by Farxiga (Dapagliflozin Propanediol). DME data shows 51 claims. No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has fallen sharply in recent years, from $83,430 to $30,017. In contrast, Part D prescription costs have risen steadily, from $50,834 to $112,386. For DME billing, this smaller-volume category fell sharply in recent years, from $3,794 to $0.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	453	1,340	$83,430
2016	399	1,296	$75,275
2017	364	1,256	$73,825
2018	352	1,137	$69,152
2019	345	1,301	$85,063
2020	249	920	$61,293
2021	137	653	$41,996
2022	214	631	$40,509
2023	49	309	$19,203
2024	68	451	$30,017

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	46	642	$50,834
2016	53	556	$61,026
2017	49	693	$40,494
2018	64	898	$63,283
2019	87	980	$86,734
2020	93	1,267	$853,643
2021	72	697	$192,160
2022	67	442	$75,948
2023	74	370	$85,423
2024	82	511	$112,386

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	143	$86,073
2016	N/R	148	$93,217
2017	N/R	52	$4,016
2018	N/R	47	$1,179
2019	N/R	205	$11,903
2020	N/R	137	$6,303
2021	N/R	297	$18,201
2022	N/R	N/R	N/R
2023	N/R	N/R	N/R
2024	N/R	51	$807

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99215	Established patient office or other outpatient visit with high level of medical decision making, if using time, 40 minutes or more	16	18	$121
99222	Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes	20	22	$111
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	23	34	$78
99232	Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes	24	186	$66
93750	Evaluation of lower heart chamber assist device	13	130	$36

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Farxiga	Dapagliflozin Propanediol	13	570	$10,977
Sildenafil Citrate	Sildenafil Citrate	42	2,670	$7,437
Sirolimus	Sirolimus	15	900	$5,555
Tacrolimus	Tacrolimus	37	2,160	$5,460
Mycophenolate Mofetil	Mycophenolate Mofetil	19	1,290	$1,919

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
J7517	Mycophenolate mofetil, oral, 250 mg	N	N/R	15	$263
Q0511	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for the first prescription in a 30-day period	N	N/R	12	$226
J7507	Tacrolimus, immediate release, oral, 1 mg	N	N/R	11	$168
Q0512	Pharmacy supply fee for oral anti-cancer, oral anti-emetic or immunosuppressive drug(s); for a subsequent prescription in a 30-day period	N	N/R	13	$150

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

Explore More Providers

FAQ

What Medicare data is available for Eugene J. Bauerlein, MD?

Tedicare shows public-source Medicare data for Eugene J. Bauerlein, MD (NPI 1841234291), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Eugene J. Bauerlein, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Eugene J. Bauerlein, MD?

Eugene J. Bauerlein, MD is linked to UNIVERSITY OF MIAMI (billing NPI 1831799055) in the available physician profile data.

Does Eugene J. Bauerlein, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.